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ABSTRACT 
The study aims to evaluate the antidepressant activity of different doses of diphenhydramine in mice at (0.5, 1, 2 mg /Kg, IP). 
Materials and Methods: The mice were divided into 5 groups for each testing methods, each group consist of five animals. Group 1 served as a 
control and was given normal saline 0.9% (5ml/kg,IP), group 2 received (20 mg /Kg, IP) fluoxetine as a standard control. Group 3, 4, 5 were treated 
with three different doses of diphenhydramine (0.5, 1, 2 mg /Kg, IP) respectively. The normal behaviors of each group of mice were evaluated after 
30 min. of drug administration. The test was used to evaluate the antidepressant activity of diphenhydramine in Open Field, Modified Forced 
Swimming Test and Tail Suspension Test 
Results: It is found that the increase in the locomotor activity in open field cage by increasing the number of square cross to (94.2±28.7) (93.2±25.6) 
(86.6±22.1) respectively according to the doses of diphenhydramine in comparison with control group (69.4±27.2) at p< 0.05. In modified forced 
swimming test, the result also showed that the administration of diphenhydramine at (0.5, 1, 2 mg /Kg, IP) were reduced the immobility time (68.8 
± 21.1) (56.4 ± 17.7) (47.6 ± 21.7) Sec. respectively in comparison with control group. In the present study, It is found that the administration of 
diphenhydramine at (0.5, 1, 2 mg /Kg,IP) were significantly increased in the swimming time (143.2 ± 16.2) (152.6 ± 18.7) (160.02 ± 15.5) Sec. Sec. 
in comparison with control group (28.8 ± 3.4) Sec.  
Conclusion: Thus, this study suggested that the administration of diphenhydramine is produced a good therapy used in the treatment of depressed 
patients without side effect . 
Keywords: Antidepressant, Tail suspended test, Open failed test, Diphenhydramine, Force swimming test. 
INTRODUCTION 
Depression is a serious mood disorder that affect of most population 
nowadays   (Yagiela et al., 2011). The main symptoms of depression 
are due to functional deficiency in the levels of monoaminergic 
transmitters’ noradrenalin, 5- hydroxytriptamine and dopamine in 
the brain (Harvey et al 2012). Drugs that increase the level of these 
neurotransmitters in the CNS showed antidepressant activity 
(Meyers 2000). The major antidepressant therapies aim to increase 
the synaptic concentration of serotonin or norepinephrine or both 
and thus normalize the neurotransmission (Jithan and Chinnalalaiah, 
2009). Selective serotonin reuptake inhibitors (SSRIs) are the most 
commonly prescribed drugs for the treatment of depression and 
several anxiety, the actions of SSRIs at  disorder (David et al., 2009). 
In the past decayed, we found drugs that inhibit reuptake of the 
neurotransmitter serotonin have antidepressant activity therefore 
increase the search for viable of antidepressant drugs with fewer 
side effects (Domino and Edward, 1999). 
 Diphenhydramine is a first generation H1 antihistamine. It the oldest 
H1 antihistaminergic drug used clinically for the treatment of many 
conditions such as   common cold, anaphylaxis, pruritus and 
Parkinsonism disease (Raphael et al., 2006). Diphenhydramine is an 
H1receptor antagonist receptor; these receptors are found in most 
part of the body such as smooth muscles, vascular endothelial cells, 
heart tissues, and the central nervous system (Yagiela et al., 2004). 
Histamine is considered as central neurotransmitters because it is 
have many criteria for a neurotransmitter substance (Montoro et al., 
2006). Brain histamine is suggested to have physiological role in 
thermoregulation, body fluid balance, sleep and wakefulness 
(Barbier and Bradbury 2007) and release of certain hormones 
(Bealer and Crowley, 1999). Brain histamine appears to play some 
biological roles in control of mood, locomotor activity, emotion and 
other behavioral functions (Leza et al, 1991, Browen et al , 2001 ). 
Histamine exist in both peripheral and central system therefore the 
disturbance in central histamine neuronal system may be 
considered as an one of behavior disorders because If histamine is  
 
 
found in high levels, the patients  are depressed, but low histamine 
levels are causes nervous, anxious and paranoid (Prousky et al 
2002). This action of histamine in neuronal system might be 
responsible on pathophysiology of depression and therefore used 
drugs that modulation of central histamine neuronal system may be 
useful in the treatment of depression (Kano et al, 2004). 
The goals of the present investigation were undertaken to evaluate 
the antidepressant effect of different doses of diphenhydramine in 
mice as a model of an  depressive state induced by (tail suspended 
test, swimming test, open field test) and the ability to treat 
depression without adverse effects. 
MATERIALS AND METHODS 
Animals  
 Healthy albino mice of either sex weighing 25-30 gm were selected 
for the study. The animals were housed under laboratory condition, 
at temperature 22± 2 °C with a natural light \ dark cycle and fed 
with standard diet. The animals were transferred to the laboratory 
environment for at least one hour before used. Each animal was used 
only one and received only one dose of the drugs tested. Animals 
were obtained from animal care house in Dentistry Collage /Mosul 
University/ Iraq. 
Experimental design  
The drugs used in this Experiment were Diphenhydramine (NDI-
IRAQ), Fluoxetine. Diphenhydramine and fluoxetine were dissolved 
in normal saline. All drugs were administered intraperitoneally (IP) 
in a volume 5ml\kg body weight. The mice were divided into 5 
groups for each testing methods, each group consist of five animals. 
Group 1 served as a control and was given normal saline 0.9% 
(5ml/kg, IP), group 2 received (20 mg /Kg, IP) fluoxetine as a 
standard control. Group 3, 4, 5 were treated with three different 
doses of diphenhydramine (0.5, 1, 2 mg /Kg, IP) respectively. The 
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normal behaviors of each group of mice were evaluated after 30 min. 
of drug administration. 
Antidepressant activity test 
Open-field test 
 The standard Open Field Test is commonly used to assess locomotor 
activity and anxiety like behaviors in laboratory animals (rats/mice) 
(Lowery et al, 2005). Parameters are measured within 5 min. into 
the open field, a wooden box of dimensions (35×35×25) cm, where 
the ground consisted of the fund divided to equal to 25 square 
dimensions (Moser et al., 1988; Molinengo et al., 1989). 
After thirty minutes of administration of fluoxetine, 
diphenhydramine, the animals were subjected to the test activity in 
the open field cage. The mouse was placed in the central square to 
measure onset to move from central square and the ambulation 
(number of squares cross)/ 5 min.          
Modified forced swimming test 
Antidepressant activities of different doses of diphenhydramine 
were assessed using modified Porsolt test (Jintanaporn et al, 2007). 
Mice were placed individually in a transparent glass cylinder (12 cm 
in diameter, height 25 cm), which was filled with water to a height of 
12 cm. 30 minutes after drugs injected the mice were forced to swim 
in the cylinder for 6 minutes.  
The following behaviors were recorded during the last 4 min 
(Moallem et al., 2007). 
 Immobility: floating in water without swimming. 
Swimming: active movements of extremities and circling in the 
container. 
Climbing: active movements of forelimbs on the container wall. 
Tail suspension test 
The Tail Suspension Test was performed according to the method 
described by Steru et al. 1985 .The principle of this test is that 
suspending mice from tail, suspended upside down of mice produce 
characteristic behavior immobility which same as to human 
depression. Thirty minutes after the administration different doses 
of diphenhydramine and fluoxetine, mice were suspended upside on 
the edge of the table 50 cm above the floor by transparent adhesive 
tape placed about 1 cm from the tip of the tail. Cumulative 
Immobility time was calculated for the last 4 min during 6 min 
period. When mice were unable to movement fore and hind limb and 
the head toward in striated line to the floor. A decrease in the 
immobility period is indicative of antidepressant-like activity (Vogal 
and Vogel, 2002). 
Statistical analysis 
The data were expressed as mean  ± SD , difference between three 
experimental groups were statistically analyzed by one way analysis 
of variance          (ANOVA) followed by the least significant difference 
test and Duncan test . The level of significance was at p < 0.05. 
RESULTS  
In the present study, the antidepressant effect of diphenhydramine 
was evaluated in mice. Thirty minutes after administration of 
fluoxetine, diphenhydramine were evaluated the antidepressant 
activity using the three test as indicated for the antidepressant effect 
of drugs in mice. 
Locomotor activity 
Administration diphenhydramine at (0.5, 1, 2 mg /Kg,IP) were found 
that increase in the locomotor activity. This indicated by increasing 
the number of square cross were (94.2±28.7) (93.2±25.6) 
(86.6±22.1) respectively according to the doses of diphenhydramine 
in comparison with control group (69.4±27.2) at p< 0.05 but this 
increase was not significant difference with standard treated group 
(Fluoxetine) (111.8±7.21) Whereas there is a significantly difference 
between control (69.4±27.2) and standard treated group 









Figure 1: Effect of diphenhydramine (0.5, 1,2 mg\kg, IP) and 
Fluoxetine (20 mg/Kg ,IP)  on Number of Square Cross in Open 
Field Test:Group1: Normal Saline.Group 2: Fluoxetine. Group 3: 
Diphenhydramine0.5mg/kg.Group 4: Diphenhydramine 
1mg/kg. Group5: Diphenhydramine 2mg/kg 
There were no significant difference in the onset time to move from 
central square between control (3.5±0.4), fluoxetine (2.8±0.6 ) and 
(2.9±0.2), (3.1±0.5), (2.8 ±0.5) Sec. respectively according to the 









Figure2: Effect of diphenhydramine (0.5, 1,2 mg\kg, IP) and 
Fluoxetine (20 mg /Kg ,IP)on Time Spend in Central Square in 
Open Field Test. Group1: Normal Saline.Group 2: Fluoxetine. 
Group 3: Diphenhydramine 0.5mg/kg. Group 4: 
Diphenhydramine 1mg/kg. Group5:Diphenhydramine 
2mg/kg. 
Modified forced swimming test 
 Administration fluoxetine significantly reduced the immobility time 
in comparison with control group (183.4 ± 21.7) Sec at p < 0.05. the 
results also showed that the administration of diphenhydramine at 
(0.5 , 1, 2  mg /Kg ,IP) were reduced the immobility time (68.8 ± 
21.1) (56.4 ± 17.7) (47.6 ± 21.7) Sec respectively in comparison with 
control group, but this decrease in immobility time significantly less 
than fluoxetine (32.4 ± 7.8)Sec in all doses of 
diphenhydramine.(Table1) 
Table1:Effect of diphenhydramine (0.5, 1,2 mg\kg, IP) and 
Fluoxetine (20 mg /Kg ,IP)  on Immobility time in Force 
Swimming Test in mice 
 
- value are mean ± SE for 5 mice /group . 
*:Significantly different from the control group at P< 0.05 . 
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The percentage of inhibition Immobility time in fluoxetine treated 
group were (86.5%) and (71.4%) (76.6%) (80.1%) respectively 
according to the doses of diphenhydramine (0.5, 1, 2 mg /Kg, IP) in 
comparison with control group (Table 1).  
In the present study we found that the administration of 
diphenhydramine at (0.5, 1, 2 mg /Kg, IP) were significantly 
increased in the swimming time (143.2 ± 16.2)     (152.6 ± 18.7) 
(160.02 ± 15.5) Sec. in comparison with control group (28.8 ± 3.4) 
Sec (Table 2), but this decrease in swimming time by 
diphenhydramine is less than fluoxetine treated group (170.8 ± 
17.7) Sec (Table 2). In the present study we found that no 
significantly difference in climbing time between groups treated 
with fluoxetine (36.8 ± 10 ) Sec. control (28.2 ± 11.1 ) and 
diphenhydramine at ( 0.5, 1, 2  mg /Kg ,IP) (28.0 ± 6.4) ( 31.2 ± 8.7 ) 
( 32.2 ± 12.8) Sec respectively (Table 2).  
Table2 :Effect of diphenhydramine (0.5, 1,2 mg\kg, IP) and 
Fluoxetine (20 mg /Kg, IP) on Swimming Time and Climbing 
Time in Force Swimming Test. 
 
- value are mean ± SE for 5 mice /group . 
 *:Significantly different from the control group at P< 0.05 . 
Tail suspension test 
Administration diphenhydramine in different doses (0.5, 1, 2 mg 
/Kg, IP) were reduced the total immobility time in tail suspended 
test in mice (72.4±9.5 ) (63±3.7 ) (57.2±9.9) respectively according 
to the doses of diphenhydramine (Table 3). Mean duration of 
cumulative immobility time was significantly decreased in fluoxetine 
(48.6±5 ) in comparison with control treated group (97.4±6.2 ). Also 
we found that the administration diphenhydramine at (0.5, 1, 2  mg 
/Kg ,IP) were produced same effects of fluoxetine by decreasing the 
duration of immobility time in comparison with control treated 
group (Table 3 ). 
Table3: Effect of diphenhydramine (0.5, 1,2 mg\kg, IP) and 
Fluoxetine (20 mg /Kg, IP) on Cumulative Immobility time in 
Tail Suspended Test in mice 
 
value are mean ± SE for 5 mice /group . 
 *:Significantly different from the control group at P< 0.05 . 
a: Significantly different from the Fluoxetine group at P< 0.05 . 
The percentage of inhibition Immobility time were (70%) (73.7%) 
(76.2%) respectively according to the doses of diphenhydramine(0.5 
, 1, 2  mg /Kg ,IP) in comparison with control  and fluoxetine group 
(79.75% ) (Table 3).  
DISCUSSION 
In the present study, antidepressant effects of different doses of 
diphenhydramine have been studied. The drug showed that it has 
antidepressant activity. The increase in locomotor activity indicates 
a stimulant effect of diphenhydramine. These results are in 
agreement with previous study suggested that H1 receptor 
antagonist effect on locomotor behavior in mice (Leza et al., 1991). 
From the results obtained by the depressant models tests used in 
this study, it can be showed that the effect of the diphenhydramine 
on the reduction of immobility time were more strongly in the 
forced-swimming model and the tail-suspension test than open field 
test. All three doses of diphenhydramine reduced immobility time 
and increased swimming time in modified forced swimming test. 
This effect of diphenhydramine may be return to the action on 
inhibition of serotonin and noradrenalin which play important role 
in in motor activity. (Volkow et al., 1998). These results are in 
agreement with other study suggested that H1 antagonist is showed 
to increase levels of noradrenalin and serotonin in the brain 
(Domino and Edward, 1999). Accumulated extracellular serotonin 
binds to receptors on the transporter, therefore changes occur in the 
transporter and serotonin, Na+, and Cl– are moved into the cell. After 
this step binding of intracellular K+ that cause in return of the 
transporter to its original conformation and the release of serotonin 
inside the cell (Katzung et al., 2012)  
The monoamine theory suggested that depression is occurring due 
to deficiency of serotonin and\or noradrenaline. In depressed 
patients showed a reduction of monoamine turnover with decrease 
levels of monoamine in cerebrospinal fluid, plasma and urine 
(Katzung et al., 2009).  For this reason, the main pharmacological 
action of antidepressant drug is the inhibition of synaptic reuptake 
of monoamine catabolism, thus increasing the levels of synaptic 
neurotransmitter (Feighner, 1999). 
In the 1960s, diphenhydramine was found to inhibit reuptake of the 
neurotransmitter serotonin (Domino and Edward, 1999). The 
central serotonergic system may play an important role in the 
locomotor activity (Risch and Nemeroff, 1992). This action is 
mediated by postsynaptic 5-HT1A receptor, which caused an 
increased in serotonin levels (Zelman and Garver 1990). In the 
modified forced swimming test, we observed that all doses of 
diphenhydramine were significantly reduced the immobility period 
and increase in the swimming time without effect on climbing time, 
this result indicated that that the diphenhydramine act as 
antidepressant due to action on serotonin reuptake inhibitors 
because antidepressant drugs that increase the swimming time is 
consider as serotonin reuptake inhibitors of serotonin while 
increase in the climbing time is occur due to norepinephrine 
reuptake inhibitors (Detke and Lucki 1996). These results are in 
agreement with other study suggested that the single injection of 
diphenhydramine reduce time of immobility (Leza et al., 1991).    
Other mechanism explanation about the antidepressant activity of 
diphenhydramine may be return to the action on H1 receptor as 
antagonist Because histamine neurotransmitter when binding with 
H1 receptor as agonist, Facilitate release of GABA neurotransmitter 
which in turn inhibits serotonin release (Payne and Neuman , 1997). 
Therefore blocking of H1 receptor by diphenhydramine abolish this 
effect of histamine i:e increase the release of serotonin as well as 
diphenhydramine inhibit the reuptake of serotonin and 
norepinephrine that cause increase the concentration of serotonin in 
nerve ending and increase activity.  
Another mechanism about the action of diphenhydramine as 
antidepressant may be due to histamine has been showed to inhibit 
noradrenaline release from nerve ending (Barbier and Bradbury, 
2007).  These actions indicated that histamine decrease the release 
of these neurotransmitter which causes depression. Therefore the 
action of diphenhydramine (H1 antagonist) prevents this action of 
histamine. Because dysfunctions of serotonergic and noradrenergic 
neurotransmitters are represented the major causes of mood and 
other neuropsychiatric disorder (Leonard, 1997, Souza et al., 2004). 
Block reuptake of serotonin causing increase serotonin in the 
synapse thus concentrated of serotonin in the cleft is alleviated 
neuronal activity (Brunton and Parker, 2008) and when used H1 
antagonist is shown cause decrease in the brain histamine levels 
(Yagiela et al, 2011 ). Therefore the effect of diphenhydramine in 
present study might be inhibiting the effect of histamine on brain 
monoaminergic system by H1 receptor blocker or decrease 
histamine release. The result of all these effects of diphenhydramine 
may be lead to an increase in monoamine level in brain. This action 
same as the action of tricyclic antidepressant which inhibit 
histamine neurotransmitter, which responsible for depression. 
There are inverse relationships between histamine and (serotonin 
and epinephrine) because patient with increased level of histamine 
have low serotonin and noradrenalin level which manifested as 
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depression (Cowen, 1990). Therefore increase the concentrations of 
serotonin and epinephrine in the synapse and prolonging their 
duration of action at postsynaptic level is the aim for used selective 
5-HT or NE reuptake inhibitors in the treatment of major depressive 
disorder (Guiard et al., 2009). 
CONCLUSION 
In the present study, we showed that administration of 
diphenhydramine in mice reverse the behavior dysfunction induced 
by tail suspended test, swimming test and open field test. Thus, our 
study suggested that the administration of diphenhydramine is 
considered a good therapy used in the treatment of depressed 
patients without side effect that produce when used some 
antidepressant drugs as well as the rapid onset of diphenhydramine 
action compare with others antidepressants drugs.  
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